Comparison of the molecular classification with FIGO stage and histological grade on endometrial cancer

Purpose of investigation: To classify endometrial cancers based on gene expression profiling, and to compare the prognostic value of the classification systems based on gene expression, grade, and stage. Methods: cDNA microarray was carried out in 32 endometrioid endometrial cancers. Differentially expressed genes were identified among tumor tissues of different grades and stages. The classification and prognosis comparison analysis was performed between histological grades, FIGO stages and gene expression profiles. Results: Class comparison analysis between different grade and stage endometrial cancer revealed 33 genes that are differentially expressed in tumors of different grades, ten in those of different stages, and 104 in a combined classification of grades and stages (p < 0.001). Conclusion: The cDNA microarray technique is a feasible way to generate gene expression profiles of endometrial cancer. Classification based on gene expression patterns may be more accurate than histological grade and FIGO stage classification in predicting the prognosis of tumors.

Gene expression profiling; Endometrial carcinoma; Classification; Prognosis

[1] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: "Endometrial cancer". Lancet, 2005, 366, 491.

[2] American College of Obstetricians and Gynecologists: "ACOG practice bulletin, clinical management guidelines for obstetriciangynecologists, number 65, August 2005: management of endometrial cancer". Obstet. Gynecol., 2005, 106, 413.

[3] Bucca G., Carruba G., Saetta A., Muti P., Castagnetta L., Smith C.P.: "Gene expression profiling of human cancers". Ann. N Y Acad Sci., 2004, 1028, 28.

[4] Quackenbush J.: "Microa订ay analysis and tumor classification" N. Engl. J. Med., 2006, 354, 2463.

[5] Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H et al.: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications". Proc. Natl. Acad. Sci. USA, 2001, 98, 10869.

[6] Alizadeh A.A., Eisen M.B.. Davis R.E., Ma C., Lossos I.S,. Rosenwald A et al.: "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling". Nature, 2000, 403, 503.

[7] Dave S.S., Fu K., Wright G.W., Lam L.T., Kluin P., Boerma E.J et al.: "Molecular diagnosis of Burkitt's lymphoma". N. Engl. J. Med., 2006, 354, 2431.

[8] van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M. et al.: "Gene expression profiling predicts clinical outcome of breast cancer". Nature, 2002, 415, 530.

[9] Ouellet V., Provencher D.M.. Maugard C.M., Le P age C., Ren F., Lussier C. et al.: "Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling". Oncogene, 2005, 24, 4672.

[10] Eisen M.B., Spellman P.T., Brown P.O., Botstein D.: "Cluster analysis and display of genome-wide expression patterns". Proc Natl. Acad. Sci USA, 1998, 95, 14863.

[11] Kitchener H.: "Management of endometrial cancer". Eur. J. Surg Oneal., 2006, 32, 838.

[12] Mutter G.L., Baak J.P., Fitzgerald J.T. et al.: "Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation". Gynecol. Oneal., 2001, 83, 177.

[13] Gunter Kieback D., Fischer D.C.: "Gene expression profile m endometrioid endometrial carcinoma". Gynecol. Oneal., 2001, 83, 175.

[14] Planaguma J., Diaz-Fuertes M., Gil-Moreno A., Abal M., Monge M., Garcia A. et al.: "A differential gene expression profile reveals overexpression of RUNXI/AML! in invasive endometrioid carcinoma". Cancer Res., 2004, 64, 8846.

[15] Smid-Koopman E., Blok L.J., Helmerhorst T.J., Chadha-Ajwam S., Burger C.W., Brinkmann A.O. et al.: "Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value". Gynecol. Oneal., 2004, 93, 292.

[16] Ferguson S.E., Olshen A.B., Viale A, Awtrey C.S., Barakat R.R., Boyd J.: "Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma". Gynecol. Oneal.. 2004, 92, 719.

[17] Risinger J.I., Maxwell G.L., Chandrarnouli G.V., Jazaeri A., Aprelikova O., Patterson T. et al.: "Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer". Cancer Res., 2003, 63, 6.

[18] Maxwell G.L., Chandramouli G.V., Dainty L., Litzi T.J., Berchuck A., Barrett J.C. et al.: "Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer". Clin. Cancer Res., 2005, 11, 4056.

[19] Bidus M.A., Risinger J.I., Chandramouli G.V., Dainty L.A., Litzi T.J., Berchuck A. et al.: "Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray". Clin. Cancer Res., 2006, 12, 83.

[20] Ferguson S.E., Olshen A.B., Viale A., Barakat R.R., Boyd J "Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles". Clin. Cancer Res., 2005, 11, 2252.

[21] Takahashi S., Hasebe T., Oda T., Sasaki S., Kinoshita T., Konishi M. et al.: "Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma". Cancer, 2002, 94, 1894.

[22] Hofer M.D., Kuefer R., Varambally S., Li H., Ma J., Shapiro G.I et al.:'The role of metastasis-associated protein I in prostate cancer progression". Cancer Res., 2004, 64, 825.

[23] Byrne J.A., Balleine R.L., Schoenberg Fejzo M., Mercieca J., Chiew Y.E., Livnat Y. et al.: "Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer". Int. J. Cancer, 2005, 117, 1049.

[24] Yamamura J., Miyoshi Y，Tamaki Y., Taguchi T., Iwao K., Monden M. et al.: "mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers". Cancer Sci., 2004, 95, 887.

[25] Park K., Kim K., Rho S.B., Choi K., Kim D., Oh S.H. et al.: "Homeobox Msx l interacts with p53 tumor suppressor and inhibits tumor growth by inducing apoptosis". Cancer Res., 2005, 65, 749.

[26] Kawamura-T suzuku J., Suzuki T., Yoshida Y., Yamamoto T "Nuclear localization of Tob is important for regulation of its antiproliferative activity". Oncogene, 2004, 23, 6630.

[27] Wang L., Yu J., Ni J., Xu X.M., Wang J., Ning H. et al.: "Extracellular matrix protein 1 (ECMl ) is over-expressed in malignant epithelial tumors". Cancer Lett., 2003, 200, 57.